-
-
-
-
-
-
-
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
-
-
-
-
-
-
-
Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean G
-
-
-
-
-
-
-
Pfizer (PFE) and Astellas PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of la/mUC
-
-
-
-
-
-
-
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
-
-
-
-
-
-
-
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
-
-
-
-
-
-
-
Astellas Provides Update on Fezolinetant New Drug Application in U.S.
-
-
-
-
-
-
-
Pfizer (PFE), Astellas Announce Final PROSPER Results Show XTANDI Significantly Extends OS in Men with Non-Metastatic Castration-Resistant Prostate Cancer
-
1,198,731 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

